Stereotactic body radiation therapy in primary liver tumor: Local control, outcomes and toxicities
SBRT provides good LC with an acceptable safety profile. It can be used in several settings such as salvage therapy or in combination with validated treatment. Prospective randomized trials are needed to validate SBRT as a standard alternative.
Authors
- Amélie Lusque (ORCID: https://orcid.org/0000-0001-9691-5536)
- F. Izar
- V. Molinier
- Bertrand Suc
- Jean‐Marie Péron (ORCID: https://orcid.org/0000-0002-7654-8449)
- L. Parent (ORCID: https://orcid.org/0000-0001-6528-2393)
- E. Cohen-Jonathan Moyal
- A. Modesto (ORCID: https://orcid.org/0000-0003-2133-6454)
- Philippe Otal
- L Arranz Hernández
Institutions
- Université Toulouse III - Paul Sabatier (FR)
- Centre de Recherches en Cancérologie de Toulouse (FR)
- Hôpital Rangueil (FR)
- Institut Claudius Regaud (FR)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1016/j.ctro.2024.100892
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37